Publications

Search our bibliography using the filters on the right-hand side.

Displaying 1 through 50 of 134 publications.

Graham J, Wolfson LJ, Kyle J, Perez Bolde-Villarreal C, Guarneros-DeRegil DB, Monsanto H, Pillsbury M, Talbird S, Daniels VJ. Budget impact analysis of multiple varicella vaccination strategies: a Mexico perspective. Hum Vaccin Immunother. 2019 Dec 18;16(4):886-94. doi: 10.1080/21645515.2019.1672491

Cawson M, Wolowacz S, Doward L, Sinha A. Health utility estimates for congenital cytomegalovirus disease: conceptual design considerations. Poster presented at the ISPOR 2019 European Conference; November 5, 2019. Copenhagen, Denmark. [abstract] Value Health. 2019 Dec; 22(S3).

Tahami Monfared AA, Stull K, Zhang Q. Staging early Alzheimer's disease using the Alzheimer's Disease Composite Score (ADCOMS). Poster presented at the 12th Clinical Trials in Alzheimer’s Disease (CTAD) Meeting; December 2019. San Diego, CA.

Lucas A, Wilson M, Sings HL, Pugh S, Jones D, Farkouh R, Gessner B, Wasserman M. Estimating the vaccine effectiveness against serotype 3 for the 13-valent pneumococcal conjugate vaccine: a dynamic modeling approach. International journal of infectious diseases and therapy. 2019 Dec;4(4):56-66. doi: 10.11648/j.ijidt.20190404.12

Aronsson M, Ling C, Stevenson A, Brodtkorb TH. Submission process and requirements of Nordic health technology assessment (HTA) authorities for hospital drugs - implications for market access strategy. Poster presented at the ISPOR 2019 European Conference; November 4, 2019. Copenhagen, Denmark. [abstract] Value Health. 2019 Dec; 22(S3).

Pearson I, Stevenson A, Krieger T, Ling C. What is the role of the company evidence submission in National Institute for Health and Care Excellence (NICE) multiple technology appraisals? Poster presented at the ISPOR 2019 European Conference; November 5, 2019. Copenhagen, Denmark. [abstract] Value Health. 2019 Dec; 22(S3).

Zhang Y, Herring WL, Martin A, Gunsoy N, Zhang W. Development of a novel economic modeling approach for asthma. Poster presented at the ISPOR 2019 European Conference; November 5, 2019. Copenhagen, Denmark. [abstract] Value Health. 2019 Dec; 22(S3).

Barnett C, Davenport MS, Montgomery JS, Kunju LP, Denton B, Piert M. 18F-choline PET/mpMRI for detection of significant prostate cancer, part 2: cost-effectiveness analysis. J Nucl Med. 2019 Dec;60(12):1705-12. doi: 10.2967/jnumed.119.225771

Gallagher J, Russell L, McAlister M, Brockbank J. Impact of gemtuzumab ozogamicin on the Irish healthcare system. Poster presented at the ISPOR 2019 European Conference; November 4, 2019. Copenhagen, Denmark. [abstract] Value Health. 2019 Dec; 22(S3).

Stull K, Esterberg E, Ajmera M, Candrilli S, Kitt TM, Spalding JR, Patel VP. Use of antifungals and outcomes among inpatients at risk of invasive aspergillosis or mucormycosis in the USA: a retrospective cohort study. Infect Dis Ther. 2019 Dec;8(4):641-55. doi: 10.1007/s40121-019-00267-4

Standaert B, Van Vlaenderen I, Van Bellinghen LA, Talbird SE, Hicks K, Carrico J, Buck PO. Constrained optimization for the selection of influenza vaccines to maximize the population benefit: a demonstration project. Appl Health Econ Health Policy. 2019 Nov 22. doi: 10.1007/s40258-019-00534-y

Kabadi SM, Goyal RK, Nagar SP, Davis KL, Le H, Du XL, Jain P, Wang ML, Romaguera JE, Kaye JA. Overall survival, adverse events, and economic burden in Medicare-insured patients with mantle cell lymphoma receiving cancer-directed therapy. Presented at the 61st American Society of Hematology (ASH) Annual Meeting and Exposition; December 7, 2019. Orlando, FL. [abstract] Blood. 2019 Nov 13; 134(Supplement_1):63. doi: 10.1182/blood-2019-122841

Allen LF, Aggarwal K, Vredenburg M, Barnett C, Mladsi D, Kim R. Cost-effectiveness of avatrombopag for the treatment of thrombocytopenia in patients with chronic liver disease. Poster presented at the 61st ASH American Society of Hematology Annual Meeting and Exposition; December 8, 2019. San Diego, CA. [abstract] Blood. 2019 Nov 13; 134(Supplement_1):3454. doi: 10.1182/blood-2019-131822

Houghton K, Dimopoulos M, Lin PL, Guillonneau S, Bury S, Attal M, Richardson PG, Delforge M. Health-related quality of life in patients with relapsed/refractory multiple myeloma treated with isatuximab plus pomalidomide and dexamethasone: Icaria-MM study. Poster presented at the 61st American Society of Hematology (ASH) Annual Meeting and Exposition; December 7, 2019. Orlando, FL. [abstract] Blood. 2019 Nov 13; 134(Supplement_1):1850. doi: 10.1182/blood-2019-128220

Goyal RK, Nagar SP, Kabadi SM, Davis KL, Le H, Kaye JA. Overall survival, adverse events, and economic burden in Medicare patients with chronic lymphocytic leukemia receiving cancer-directed therapy. Presented at the 61st American Society of Hematology (ASH) Annual Meeting and Exposition; December 9, 2019. Orlando, FL. [abstract] Blood. 2019 Nov 13; 134(Supplement 1):796. doi: 10.1182/blood-2019-122842

Xie J, Yong A, Waweru C, Sorof TA, Goyal RK, Davis KL, Fellows G, Hillmen P. Real-world treatment patterns and adverse events in patients with chronic lymphocytic leukemia treated with ibrutinib in the UK: a preliminary analysis. Poster presented at the 61st American Society of Hematology (ASH) Annual Meeting and Exposition; December 2019. Orlando, FL. [abstract] Blood. 2019 Nov 13; 134(Supplement_1):5885. doi: 10.1182/blood-2019-123025

Brazier JE, Knight H, Wolowacz SE. Including caregiver / family member quality of life in economic evaluations – your questions answered. Presented at the ISPOR 2019 European Conference; November 6, 2019. Copenhagen, Denmark.

Igarashi A, Kusel J, Pearson I, Ronquest N. Do innovative technologies require innovative appraisal techniques? - case studies from recent HTAs in the UK, US and Japan. Presented at the ISPOR 2019 European Conference; November 4, 2019. Copenhagen, Denmark.

Knight C, Pearson I. Economic modelling considerations for rare diseases. Presented at the ISPOR 2019 European Conference; November 4, 2019. Copenhagen, Denmark.

Earnshaw SR, Brogan A, Brodtkorb TH. Budget impact analysis II - applications & design issues. Presented at the ISPOR 2019 European Conference; November 3, 2019. Copenhagen, Denmark. Previously presented at the ISPOR 20th Annual International Meeting.

Mullins CD, Earnshaw SR, Brodtkorb TH. Budget impact analysis I: a 6-step approach. Presented at the ISPOR 2019 European Conference; November 3, 2019. Copenhagen, Denmark. Previously presented at the ISPOR 18th Annual European Congress.

Ling W, Nadipelli VR, Solem CT, Ronquest NA, Yeh YC, Learned SM, Mehra V, Heidbreder C. Patient-centered outcomes in participants of a buprenorphine monthly depot (BUP-XR) double-blind, placebo-controlled, multicenter, phase 3 study. J Addict Med. 2019 Nov;13(6):442-9. doi: 10.1097/ADM.0000000000000517.

Carreno JJ, Tam IM, Meyers JL, Esterberg E, Candrilli SD, Lodise TP. Longitudinal, nationwide, cohort study to assess incidence, outcomes, and costs associated with complicated urinary tract infection. Open Forum Infect Dis. 2019 Nov;6(11):ofz446. doi: 10.1093/ofid/ofz446

Brogan AJ, Talbird SE, Davis AE, Wild L, Flanagan D. Is increased screening and early antiretroviral treatment for HIV-1 worth the investment? An analysis of the public health and economic impact of improvement in the UK. HIV Med. 2019 Nov;20(10):668-80. doi: 10.1111/hiv.12788

Wilson M, Moffatt M, Mignon A, McDade C, Wasserman M. Potential public health impact model assessing the switch back to use of the 13-valent infant pneumococcal conjugate vaccine in Belgium on children under 18 years. Poster presented at the World Society for Pediatric Infectious Diseases (WSPID) Conference; November 2019. Manila, Philippines.

Vickers A. An evaluation of survival curve extrapolation techniques using long-term observational cancer data. Med Decis Making. 2019 Nov;39(8):926-38. doi: 10.1177/0272989X19875950

Savatt JA, Azzariti DR, Faucett A, Florin J, Ledbetter DH, Rangel Miller V, Palen E, Rehm HL, Rhode J, Rogers L, Talbird S, Trutoiu L, Vidal JA, Waggoner C, Rooney Riggs E, Lese Martin C. Expanding patient data sharing: GenomeConnect's pilot to engage external registries in data sharing. Poster presented at the 2019 National Society of Genetic Counselors (NSGC) 38th Annual Conference; November 2019. Salt Lake City, UT.

Khurana N, Farnham PG, Hicks KA, Carrico J, Sansom S. Impact of targeting pre-exposure prophylaxis to individual transmission groups in the United States. Poster presented at the 2019 INFORMS Annual Meeting; October 20, 2019. Seattle, WA.

Ueda K, Takura T, Fujikoshi S, Meyers J, Nagar SP, Enomoto H. A claims database longitudinal study of the economic burden among patients with knee osteoarthritis in Japan. Poster presented at the 34th Annual Research Meeting of the Japanese Orthopaedic Association; October 17, 2019. Yokohama, Japan.

Lucas A, Sinha A, Fowler KB, Mladsi D, Barnett C, Samant S, Gibson L. A framework for assessing the lifetime economic burden of congenital cytomegalovirus in the United States. Cost Eff Resour Alloc. 2019 Oct 3;17(1):21. doi: 10.1186/s12962-019-0189-0

Carrico J, Jia X, Zhao Y, Zhang J, Brodtkorb T, Mendelsohn A, Wu J, Feldman S, Armstrong A. Cost-effectiveness and budget impact of tildrakizumab for the treatment of moderate to severe plaque psoriasis using 2019 drug costs. Poster presented at the 2019 AMCP NEXUS; October 29, 2019. National Harbor, MD. [abstract] J Manag Care Spec Pharm. 2019 Oct; 25(10-a Suppl):S79. doi: 10.18553/jmcp.2019.25.10-a.s1

Candrilli SD, Kurosky SK. The response to and cost of meningococcal disease outbreaks in university campus settings: a case study in Oregon, United States. 2019. Research Triangle Park: RTI Press. doi: 10.3768/rtipress.2019.rr.0034.1910

Wheeler A, Ling W, Nadipelli V, Ronquest N, Aldridge A, Solem C, Peiper N, Learned S, Heidbreder C. Recovery from opioid use disorder post-monthly buprenorphine extended release treatment: 12-month longitudinal outcomes. Poster presented at the 2019 AMCP NEXUS; October 29, 2019. National Harbor, MD. [abstract] J Manag Care Spec Pharm. 2019 Oct; 25(10-a):S14. doi: 10.18553/jmcp.2019.25.10-a.s1

Fan W, Nittala MG, Velaga SB, Hirano T, Wykoff CC, Ip M, Lampen SIR, van Hemert J, Fleming A, Verhoek M, Sadda SR. Distribution of nonperfusion and neovascularization on ultrawide-field fluorescein angiography in proliferative diabetic retinopathy (RECOVERY study): report 1. Am J Ophthalmol. 2019 Oct 1;206:154-60. doi: 10.1016/j.ajo.2019.04.023

Goyal RK, Cuyun Carter G, Nagar SP, Smyth EN, Price GL, Huang YJ, Li L, Davis KL, Kaye JA. Treatment patterns, survival, and economic outcomes in Medicare-enrolled, older patients with HR+/HER2– metastatic breast cancer. Curr Med Res Opin. 2019 Oct;35(10):1699-710. doi: 10.1080/03007995.2019.1615422

Meyers JL, Davis KL, Lenz RA, Sakai F, Xue F. Treatment patterns and characteristics of patients with migraine in Japan: a retrospective analysis of health insurance claims data. Cephalalgia. 2019 Oct;39(12):1518-34. doi: 10.1177/0333102419851855

Purser M, Bhaila R, Hartley L, Earnshaw S, Nag A. Economic evaluations of biological treatments for moderate-to-severe Crohn's Disease: findings from a systematic literature review. Poster presented at the 2019 United European Gastroenterology UEG Week; October 23, 2019. Barcelona, Spain. [abstract] United European Gastroenterol J. 2019 Oct; 7:907.

Purser M, Bhaila R, Hartley L, Earnshaw S, Nag A. The economic burden of Crohn's disease in Europe: findings from a systematic literature review. Poster presented at the 2019 27th United European Gastroenterology UEG Week; October 23, 2019. Barcelona, Spain. [abstract] United European Gastroenterol J. 2019 Oct; 7:906.

Brufsky A, Mitra D, Davis KL, Nagar SP, McRoy L, Cotter MJ, Stearn V. Treatment patterns and outcomes associated with palbociclib plus letrozole for postmenopausal women with HR-/HER2– advanced breast cancer enrolled in an expanded access program. Clin Breast Cancer. 2019 Oct;19(5):317-25. doi: 10.1016/j.clbc.2019.04.005

Patterson BJ, Herring W, van Oorschot D, Curran D, Carrico J, Zhang Y, Ackerson BK, Bruxvoort K, Sy L, Tseng H. Public health and economic impact of adjuvanted recombinant zoster vaccine adoption for a large, integrated delivery network: utilizing real‐world epidemiological data in a budget impact model. Poster presented at the 2019 AMCP NEXUS; October 29, 2019. National Harbor, DC. [abstract] J Manag Care Spec Pharm. 2019 Oct; 25(10-a):S23.

Govindan R, Senan S, Dickgreber N, Provencio M, Wu YL, Syrigos K, Parente B, Wilson M, Ziemiecki R, Chouaki N, Hossain A, San Antonio B, Winfree K, Vokes EE. Healthcare resource utilization and associated cost analysis of the PROCLAIM study in patients with stage III non-small-cell lung cancer. Curr Med Res Opin. 2019 Oct;35(10):1761-7. doi: 10.1080/03007995.2019.1623185

Shah R, Girard N, Nagar S, Griesinger F, Roeper J, Davis KL, Bakker NA, Thakrar B, Taylor A, Feliciano J. Real-world (RW) treatment patterns and outcomes for second-line (2L) therapy and beyond in patients (pts) with epidermal growth factor receptor mutated (EGFRm) advanced NSCLC receiving a first-line (1L) first- or second generation (1G/2G) EGFR tyrosine kinase inhibitor (TKI). Poster presented at the ESMO 2019 Congress; September 27, 2019. Barcelona, Spain.

Mazieres J, Ahn MJ, Chouaid C, Kron A, Wolf J, Goyal RK, Davis KL, Perrinjaquet M, Pham T, Knoll S. Genetic testing patterns, treatment characteristics, and overall survival in ALK-positive metastatic NSCLC patients treated with Ceritinib. Poster presented at the 2019 World Conference on Lung Cancer; September 8, 2019. Barcelona, Spain.

Suzuki O, Dong OM, Howard RM, Wiltshire T. Characterizing the pharmacogenome using molecular inversion probes for targeted next-generation sequencing. Pharmacogenomics. 2019 Sep;20(14):1005-20. doi: 10.2217/pgs-2019-0057

Herring W. The song remains the same: recurring themes and persistent challenges in Alzheimer's disease modeling. Presented at the International Pharmacoeconomic Collaboration on Alzheimer’s Disease (IPECAD) Workshop on Health Economic Modelling in AD; September 2019. Saltsjobaden, Sweden.

Tomita T, Sato M, Parikh RC, Esterberg E, Kurosky SK, Hagimori K, Nakajo K. Treatment patterns among Japanese patients with ankylosing spondylitis (AS): hospital claims database analysis. Poster presented at the 29th Japanese Spondyloarthritis Society Conference; September 2019.

Davenport MS, Montgomery JS, Kunju LP, Siddiqui J, Shanka PR, Rajendiran T, Shao X, Lee E, Barnett CL, Denton BT, Piert M. 18F-choline PET/mpMRI for detection of clinically significant prostate cancer: Part 1. Improved risk stratification for MRI-guided transrectal prostate biopsies. J Nucl Med. 2019 Aug 16. doi: 10.2967/jnumed.119.225789.

Saif MW, Parikh R, Ray D, Kaye JA, Kurosky SK, Thomas K, Ramirez RA, Halfdanarson TR, Beveridge TJR, Mirakhur B, Nagar SP, Soares HP. Medical record review of transition to lanreotide following octreotide for neuroendocrine tumors. J Gastrointest Oncol. 2019 Aug;10(4):674-87. doi: 10.21037/jgo.2019.03.11

Mody FV, Goyal RK, Ajmera M, Cainzos-Achirica M, Davis KL, Lindstrom RC, Globe G, Riebman JB, Wirtz HS, Amin A. Exploring the association between heart rate control and patient outcomes: a retrospective medical record review of patients hospitalized with systolic heart failure. Poster presented at the 2019 Heart Failure Society of America 23rd Annual Scientific Meeting; September 14, 2019. Philadelphia, PA. [abstract] J Card Fail. 2019 Aug; 25(8 Supplement):S156. doi: 10.1016/j.cardfail.2019.07.447

Mauskopf JM, Herring WL, Zhang Y, Tahami Monfared AA. The variability in input parameter values in models estimating the effectiveness of hypothetical disease modifying treatments for Alzheimer's disease. Poster presented at the 2019 Alzheimer's Association International Conference (AAIC); July 14, 2019. Los Angeles, CA.